Rocket


Overview
Financials
News + Filings
IR Vault
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Director departure
Appointed director
CC transcript
UROLOGIX INC (ULGX) Create: Alert

All | News | Filings
Date FiledTypeDescription
07/10/2015 8-K Form 8-K - Current report
05/13/2015 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits
Docs: "Recent Quarter Results"
03/23/2015 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Letter Agreement Regarding Offer of Employment by Urologix, Inc. and Scott M. Madson",
"Letter Agreement Regarding Change In Control Benefits between Urologix, Inc. and Scott M. Madson",
"Urologix Announces Hiring of Chief Financial Officer"
02/06/2015 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits
Docs: "Urologix, Inc. Statements of Operations Three Months Ended December 31, Six Months Ended December 31, 2014 2013 2014 2013 Sales $ 3,079 $ 3,806 $ 6,100 $ 7,585 Cost of goods sold 1,615 2,008 3,174 3,923 Gross profit 1,464 1,798 2,926 3,662 Costs and expenses: Sales and marketing 729 1,681 1,539 3,527 General and administrative 467 561 955 1,246 Research and development 337 452 671 874 Change in value of acquisition consideration — — Medical device tax 48 59 96 119 Amortization expense 17 22 40 44 Total costs and expenses 1,598 2,690 3,301 5,717 Operating loss Interest expense Foreign currency exchange gain/ 1 2 Loss before income taxes Income tax expense 4 16 9 28 Net loss $ $ $ $ Net loss per common share--basic $ $ $ $ Net loss per common share--diluted $ $ $ $ Weighted average num..."
01/12/2015 8-K Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits
Docs: "Urologix Reports Preliminary Fiscal Year 2015 Second Quarter Revenue and Cash Results"
11/10/2014 8-K Submission of Matters to a Vote of Security Holders
11/05/2014 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits
Docs: "Urologix, Inc. Statements of Operations"
09/25/2014 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
08/20/2014 8-K Quarterly results
Docs: "Urologix, Inc. Statements of Operations Three Months Ended June 30, Twelve Months Ended June 30, 2014 2013 2014 2013 Sales $ 3,294 $ 4,184 $ 14,235 $ 16,590 Cost of goods sold 1,711 2,279 8,142 8,407 Gross profit 1,583 1,905 6,093 8,183 Costs and expenses: Sales and marketing 1,011 2,080 5,850 7,719 General and administrative 526 421 2,299 2,515 Research and development 344 514 1,625 2,269 Change in value of acquisition consideration — Impairment of goodwill 3,036 — 3,036 — Gain on demutualization — — — Impairment of identifiable intangible assets — 160 — 160 Medical device tax 51 65 223 106 Amortization expense 23 26 95 104 Total costs and expenses 4,991 3,187 13,023 12,105 Operating loss Interest expense Gain on debt extinguishment — 206 — 206 Foreign currency exchange gain/ 2 Loss..."
08/19/2014 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
05/07/2014 8-K Quarterly results
Docs: "Three Months Ended March 31, Nine Months Ended March 31, 2014 2013 2014 2013 Sales $ 3,356 $ 4,082 $ 10,941 $ 12,405 Cost of goods sold 2,507 2,056 6,431 6,127 Gross profit 849 2,026 4,510 6,278 Costs and expenses: Sales and marketing 1,313 1,915 4,839 5,639 General and administrative 527 711 1,773 2,094 Research and development 408 538 1,281 1,756 Change in value of acquisition consideration — Gain on demutualization — — Medical device tax 52 41 172 41 Amortization expense 28 26 72 78 Total costs and expenses 2,316 2,910 8,032 8,918 Operating loss Interest expense Foreign currency exchange gain/ 1 Loss before income taxes Income tax expense 18 17 46 48 Net loss $ $ $ $ Net loss per common share--basic $ $ $ $ Net loss per common share--diluted $ $ $ $ Weighted average number of co..."
04/16/2014 8-K Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits
Docs: "Urologix Announces Strategic Restructuring, Reports Preliminary Revenue and Cash Results for the Third Quarter of Fiscal Year 2014 • Third quarter revenue totaled $3.4 million • Cash balance of $816 thousand as of March 31, 2014 MINNEAPOLIS — April 10, 2014— Urologix®, Inc. , the leading provider of in-office procedures for the safe, durable and effective treatment of BPH, today announced a strategic restructuring of its organizational infrastructure and reported preliminary financial results for its fiscal year 2014 third quarter ended March 31, 2014. Strategic Restructuring of Organizational Infrastructure The strategic reorganization builds upon the Company’ s initiative, announced in the second quarter, to refocus the allocation of company resources and improve long-term profitability...."
03/27/2014 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "Countersigned Letter from Medtronic, Inc. to Urologix, Inc."
02/05/2014 8-K Quarterly results
Docs: "Urologix, Inc. Statements of Operations Three Months Ended December 31, Six Months Ended December 31, 2013 2012 2013 2012 Sales $ 3,806 $ 4,354 $ 7,585 $ 8,324 Cost of goods sold 2,008 2,117 3,923 4,072 Gross profit 1,798 2,237 3,662 4,252 Costs and expenses: Sales and marketing 1,681 2,007 3,527 3,724 General and administrative 561 646 1,246 1,383 Research and development 452 602 874 1,218 Change in value of acquisition consideration Medical device tax 59 — 119 — Amortization expense 22 26 44 52 Total costs and expenses 2,690 3,066 5,717 6,008 Operating loss Interest expense Foreign currency exchange gain/ 1 2 2 Loss before income taxes Income tax expense 16 16 28 32 Net loss $ $ $ $ Net loss per common share--basic $ $ $ $ Net loss per common share--diluted $ $ $ $ Weighted avera..."
02/04/2014 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "Third Amendment to Loan and Security Agreement by and between Silicon Valley Bank and Urologix, Inc"
01/10/2014 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "Second Amendment to Loan and Security Agreement by and between Silicon Valley Bank and Urologix, Inc"
01/08/2014 8-K Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits
Docs: "Strategic Restructuring of Sales and Operating Infrastructure The strategic restructuring is designed to refocus the allocation of resources and improve Company profitability. The restructuring includes both a reorganization of the Company’ s operating groups and the deployment of a more focused sales team structure. All affected employees have been notified. The Company estimates that as a result of this program, it will be able to reduce pre-tax operating expenses by more than $1.5 million annually, beginning in the third quarter of fiscal year 2014. The deployment is designed to focus our field sales and mobile organization on the Company’ s strongest urology partners. These accounts, together, represent approximately 90% of US Company revenue and have demonstrated improving trends in r..."
11/08/2013 8-K/A Form 8-K/A - Current report [Amend]
11/08/2013 8-K Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
Docs: "Articles of Amendment to Urologix, Inc. Amended and Restated Articles of Incorporation adopted effective November 7, 2013"
10/30/2013 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits
Docs: "Three Months Ended September 30, 2013 2012 Sales $ 3,779 $ 3,970 Cost of goods sold 1,915 1,954 Gross profit 1,864 2,016 Costs and expenses: Sales and marketing 1,845 1,717 General and administrative 685 738 Research and development 421 615 Change in value of acquisition consideration Medical device tax 61 - Amortization 23 26 Total costs and expenses 3,026 2,942 Operating loss Interest expense Foreign currency exchange gain/ 1 Loss before income taxes Income tax expense 12 16 Net loss $ $ Net loss per common share--basic $ $ Net loss per common share--diluted $ $ Weighted average number of common shares outstanding--basic 21,020 20,180 Weighted average number of common shares outstanding--diluted 21,020 20,180",
"Statements of Brian J. Smrdel, Chief Financial Officer, of Urologix, Inc. at a telephone conference held on October 29, 2013"
08/20/2013 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
06/05/2013 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and...
Docs: "Urologix to Transfer from NASDAQ to the OTCQB Marketplace"
05/02/2013 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits
Docs: "Urologix Reports Fiscal Year 2013 Third Quarter Results and Reaffirms Annual Guidance Third Quarter Summary",
"Certain remarks of Brian J. Smrdel, Chief Financial Officer, at a telephone conference held on May 1, 2013"
03/06/2013 8-K Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits
Docs: "Letter from KPMG LLP to the Securities and Exchange Commission"
12/06/2012 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "First Amendment to Loan and Security Agreement by and between Silicon Valley Bank and Urologix, Inc"
11/27/2012 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Letter Agreement between Urologix, Inc. and Stryker Warren, Jr.",
"Urologix Announces Leadership Change"
11/19/2012 8-K Submission of Matters to a Vote of Security Holders
08/27/2012 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits
Docs: "Urologix Reports Results for Fourth Quarter and Fiscal Year 2012",
"Certain remarks of Brian J. Smrdel, Chief Financial Officer, at a telephone conference held on August 23, 2012"
08/14/2012 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
08/09/2012 8-K Other Events, Financial Statements and Exhibits
Docs: "Urologix Announces Closing of Over-Allotment Option"
07/24/2012 8-K Form 8-K - Current report
07/05/2012 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits
Docs: "Urologix Announces Pricing of Follow-On Offering of 5,200,000 Shares of Common Stock",
"Urologix Announces Closing of Follow-On Offering"
04/27/2012 8-K Form 8-K - Current report
04/25/2012 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Amended and Restated Letter Agreement Regarding Change In Control Benefits between Urologix, Inc. and Certain Executive Officers"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy